145 related articles for article (PubMed ID: 15990222)
1. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
Metzinger DS; Taylor DD; Gercel-Taylor C
Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
[TBL] [Abstract][Full Text] [Related]
2. Clonal heterogeneity of p53 mutations in ovarian cancer.
Manahan KJ; Taylor DD; Gerçel-Taylor C
Int J Oncol; 2001 Aug; 19(2):387-94. PubMed ID: 11445857
[TBL] [Abstract][Full Text] [Related]
3. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
4. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
5. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
6. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
7. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
[TBL] [Abstract][Full Text] [Related]
8. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
Guntur VP; Waldrep JC; Guo JJ; Selting K; Dhand R
Anticancer Res; 2010 Sep; 30(9):3557-64. PubMed ID: 20944137
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
[TBL] [Abstract][Full Text] [Related]
11. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
[TBL] [Abstract][Full Text] [Related]
14. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
16. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
17. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
18. Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
Aunoble B; Bernard-Gallon D; Bignon YJ
Oncol Rep; 2001; 8(3):663-8. PubMed ID: 11295099
[TBL] [Abstract][Full Text] [Related]
19. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.
Li J; Liu P; Mao H; Wanga A; Zhang X
Oncol Rep; 2009 Jun; 21(6):1605-10. PubMed ID: 19424643
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]